159 related articles for article (PubMed ID: 22287854)
1. Detemir as a once-daily basal insulin in type 2 diabetes.
Nelson SE
Clin Pharmacol; 2011; 3():27-37. PubMed ID: 22287854
[TBL] [Abstract][Full Text] [Related]
2. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007; 29 Spec No():1254-70. PubMed ID: 18046926
[TBL] [Abstract][Full Text] [Related]
3. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
4. Insulin detemir: a long-acting insulin product.
Jones MC; Patel M
Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
[TBL] [Abstract][Full Text] [Related]
5. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus.
Rossetti P; Porcellati F; Fanelli CG; Perriello G; Torlone E; Bolli GB
Arch Physiol Biochem; 2008 Feb; 114(1):3-10. PubMed ID: 18465353
[TBL] [Abstract][Full Text] [Related]
6. Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog.
Young JR; McAdam-Marx C
Clin Med Insights Endocrinol Diabetes; 2010; 3():65-80. PubMed ID: 22879788
[TBL] [Abstract][Full Text] [Related]
7. The Comparative Dosing and Glycemic Control of Intermediate and Long-Acting Insulins in Adult Patients With Type 1 and 2 Diabetes Mellitus.
Kabakov A; Merker A
J Pharm Technol; 2022 Feb; 38(1):46-53. PubMed ID: 35141727
[TBL] [Abstract][Full Text] [Related]
8. Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus.
Kusunoki Y; Katsuno T; Miyakoshi K; Ikawa T; Nakae R; Ochi F; Tokuda M; Akagami T; Murai K; Miuchi M; Hamaguchi T; Miyagawa J; Namba M
Diabetes Ther; 2013 Dec; 4(2):461-72. PubMed ID: 24282104
[TBL] [Abstract][Full Text] [Related]
9. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
Philis-Tsimikas A
Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
[TBL] [Abstract][Full Text] [Related]
10. EADSG Guidelines: Insulin Therapy in Diabetes.
Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
[TBL] [Abstract][Full Text] [Related]
11. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
12. How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
Marks JB
Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):490-1. PubMed ID: 18594486
[TBL] [Abstract][Full Text] [Related]
13. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
14. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.
Meneghini L; Mersebach H; Kumar S; Svendsen AL; Hermansen K
Endocr Pract; 2011; 17(5):727-36. PubMed ID: 21550957
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
17. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
Frier BM; Russell-Jones D; Heise T
Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
19. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
20. Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.
Poon K; King AB
Drug Healthc Patient Saf; 2010; 2():213-23. PubMed ID: 21701633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
